for adults with T2DM
For controlled trials data, changes from the baseline were first measured and then mean differences [95% CI] between GLP-1-based therapy patients and controls were calculated for each study and then overall effect size of the meta-analysis was generated
Supplies Needed Peptide Vials (10 mg blend each): 8 weeks: 4 vials 12 weeks: 6 vials 16 weeks: 8 vials Insulin Syringes (U-100): Daily injections 7 syringes/week 8 weeks: 56 syringes 12 weeks: 84 syringes 16 weeks: 112 syringes Bacteriostatic Water (10 mL bottles): 3 mL per vial for reconstitution 8 weeks: 12 mL 2 10 mL bottles 12 weeks: 18 mL 2 10 mL bottles 16 weeks: 24 mL 3 10 mL bottles Alcohol Swabs: One for vial, one for injection site daily
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants with Vascular Disease (VERTIS-CV), which compared ertugliflozin with placebo showed non-inferiority in regards to its primary MACE outcome, as well as a 30% reduction in HHF [41]
Write the reconstitution date directly on your vial with a permanent marker
Compounded vs brand-name: what matters for your dosage chart The primary practical differences between compounded semaglutide with B12 and brand-name Wegovy come down to concentration variability, injection volume, and cost